Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to determine the maximum tolerated dose (MTD) of
Carboxyamidotriazole Orotate (CTO) when combined with standard dosing of bevacizumab among
patients with recurrent malignant glioma (WHO grade III or IV) that have previously failed
bevacizumab (Phase 1); to determine the activity of CTO alone in bevacizumab-failure WHO
grade IV malignant glioma patients (Phase 2, Arm 1); to determine the activity of CTO plus
bevacizumab in bevacizumab-failure WHO grade IV malignant glioma patients (Phase 2, Arm 2).
This study was terminated early due to funding issues. At the time of termination, the study
was still in Phase 1 and no MTD for the combination of CTO and bevacizumab had been
determined for this population. Phase 2 will not proceed.